Omeros Corporation s trend and data analysis indicates that the stock price has dropped -0.09% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -5.56% . Looking at the past 52 week period, the stock price is down -29.4% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Omeros Corporation has a negative value of -26.87 compared to overall market performance.Omeros Corporation is having a Relative Strength Index of 41.57 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Omeros Corporation (NASDAQ:OMER) has tumbled 7.71% during the past week and has dropped 4.36% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.93%. Omeros Corporation (NASDAQ:OMER) has underperformed the index by 5.45% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. Omeros Corporation (NASDAQ:OMER) stock ended Friday session in the red zone in a volatile trading. The stock closed down 1.06 points or 9.14% at $10.54 with 1,432,509 shares getting traded. Post opening the session at $11.82, the shares hit an intraday low of $10.52 and an intraday high of $12 and the price was in this range throughout the day. The company has a market cap of $452 million and the number of outstanding shares has been calculated to be 42,915,928 shares. The 52-week high of Omeros Corporation (NASDAQ:OMER) is $16.375 and the 52-week low is $7.2.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Omeros Corporation was Reiterated by Needham on Mar 17, 2017 to Buy, Lowers Price Target to $ 22 from a previous price target of $24 .Company shares were Reiterated by Maxim Group on Mar 17, 2017 to Buy, Raises Price Target to $ 22 from a previous price target of $19 .
Company has reported several Insider transactions to the SEC, on Dec 16, 2016, Thomas J. Cable (director) sold 3,000 shares at 10.21 per share price.On Dec 7, 2016, Gregory A Md Demopulos (Chairman, CEO & President) sold 306,124 shares at 10.66 per share price.On Sep 16, 2016, Marcia S. Kelbon (VP Patent and General Counsel) sold 16,000 shares at 10.91 per share price.
Omeros Corporation Last issued its quarterly earnings results on Mar 16, 2017. The company reported $-0.45 EPS for the quarter, beating the analyst consensus estimate by $ 0.11. Analyst had a consensus of $-0.56. The company had revenue of $12.90 million for the quarter, compared to analysts expectations of $12.64 million. The companys revenue was up 93.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.52 EPS.
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.